Abstract
Neurodegenerative diseases (NDDs) have been increasing in incidence in recent years and are now widespread worldwide. Neuronal death is defined as the progressive loss of neuronal structure or function which is closely associated with NDDs and represents the intrinsic features of such disorders. Amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s, Parkinson’s, and Huntington’s diseases (AD, PD, and HD, respectively) are considered neurodegenerative diseases that affect a large number of people worldwide. Despite the testing of various drugs, there is currently no available therapy that can remedy or effectively slow the progression of these diseases. Nanomedicine has the potential to revolutionize drug delivery for the management of NDDs. The use of nanoparticles (NPs) has recently been developed to improve drug delivery efficiency and is currently subjected to extensive studies. Nanoengineered particles, known as nanodrugs, can cross the blood–brain barrier while also being less invasive compared to the most treatment strategies in use. Polymeric, magnetic, carbonic, and inorganic NPs are examples of NPs that have been developed to improve drug delivery efficiency. Primary research studies using NPs to cure AD are promising, but thorough research is needed to introduce these approaches to clinical use. In the present review, we discussed the role of metal-based NPs, polymeric nanogels, nanocarrier systems such as liposomes, solid lipid NPs, polymeric NPs, exosomes, quantum dots, dendrimers, polymersomes, carbon nanotubes, and nanofibers and surfactant-based systems for the therapy of neurodegenerative diseases. In addition, we highlighted nanoformulations such as N-butyl cyanoacrylate, poly(butyl cyanoacrylate), d-penicillamine, citrate-coated peptide, magnetic iron oxide, chitosan (CS), lipoprotein, ceria, silica, metallic nanoparticles, cholinesterase inhibitors, an acetylcholinesterase inhibitors, metal chelators, anti-amyloid, protein, and peptide-loaded NPs for the treatment of AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
References
Heemels MT (2016) Neurodegenerative diseases. Nature 539(7628):179. https://doi.org/10.1038/539179a
Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 368(14):1326–1334. https://doi.org/10.1056/NEJMsa1204629
Dhall R, Kreitzman DL (2016) Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology 86(14 Suppl 1):S13-24. https://doi.org/10.1212/WNL.0000000000002510
Habib S, Singh M (2022) Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review. Polymers (Basel) 14(4):712. https://doi.org/10.3390/polym14040712
Pihlstrom L, Wiethoff S, Houlden H (2017) Genetics of neurodegenerative diseases: an overview. Handb Clin Neurol 145:309–323. https://doi.org/10.1016/B978-0-12-802395-2.00022-5
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72(2):245–256. https://doi.org/10.1016/j.neuron.2011.09.011
Hickman RA, Faustin A, Wisniewski T (2016) Alzheimer disease and its growing epidemic: risk factors, biomarkers, and the urgent need for therapeutics. Neurol Clin 34:941–953. https://doi.org/10.1016/j.ncl.2016.06.009
Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, Dash A (2016) Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther 22(3):159–166. https://doi.org/10.1111/cns.12484
Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B et al (2017) The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer’s Dement 13(1):1–7. https://doi.org/10.1016/j.jalz.2016.07.150
Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Kivipelto M (2014) Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Int Med 275:251–283. https://doi.org/10.1111/joim.12191
Jellinger KA (2020) Neuropathological assessment of the Alzheimer spectrum. J Neural Transm 127:1229–1256. https://doi.org/10.1007/s00702-020-02232-9
Nisbet RM, Polanco JC, Ittner LM, Götz J (2015) Tau aggregation and its interplay with amyloid-β. Acta neuropathol 129:207–220. https://doi.org/10.1007/s00401-014-1371-2
Canevelli M, Remoli G, Bacigalupo I, Valletta M, Toccaceli Blasi M, Sciancalepore F et al (2020) Use of biomarkers in ongoing research protocols on Alzheimer’s disease. J Pers Med 10(3):68. https://doi.org/10.3390/jpm10030068
Cauwenberghe CV, Broeckhoven CV, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421–430. https://doi.org/10.1038/gim.2015.117
Li H, Liu CC, Zheng H, Huang TY (2018) Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease-conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl Neurodegener 7:34. https://doi.org/10.1186/s40035-018-0139-3
Cummings J (2019) The role of biomarkers in Alzheimer’s disease drug development. Adv Exp Med Biol 1118:29–61. https://doi.org/10.1007/978-3-030-05542-4_2
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539–547. https://doi.org/10.1212/WNL.0000000000002923
Mobed A, Hasanzadeh M (2020) Bioassays: The best alternative for conventional methods in detection of Alzheimer’s disease biomarkers. Int J Biol Macromol 161:59–71. https://doi.org/10.1016/j.ijbiomac.2020.05.257
Weller J, Budson A (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res 7:F1000 Faculty Rev-1161. https://doi.org/10.12688/f1000research.14506.1
Selkoe DJ (2011) Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med 17:1060–1065. https://doi.org/10.1038/nm.2460
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318(7184):633–638. https://doi.org/10.1136/bmj.318.7184.633
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122–126. https://doi.org/10.1002/ana.410100203
Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimer’s Dis 67:779–794. https://doi.org/10.3233/JAD-180766
(2014) Namzaric (memantine hydrochloride extended release/donepezil hydrochloride) capsules. US Food and Drug Administration. Accessed May 17, 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm
Tezel G, Timur SS, Bozkurt İ, Türkoğlu ÖF, Eroğlu İ, Nemutlu E et al (2019) Snapshot on the current status of Alzheimer’s disease, treatment perspectives, in-vitro and in-vivo research studies and future opportunities. Chem Pharm Bull 67(10):1030–1041. https://doi.org/10.1248/cpb.c19-00511
Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD (2022) Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review. Health Psychol Res 10(1):31925. https://doi.org/10.52965/001c.31925
Hwang SR, Kim K (2014) Nano-enabled delivery systems across the blood–brain barrier. Arch Pharm Res 37:24–30. https://doi.org/10.1007/s12272-013-0272-6
Fessel W (2017) Concordance of several subcellular interactions initiates Alzheimer’s dementia: their reversal requires combination treatment. Am J Alzheimers Dis Other Demen 32:166–181. https://doi.org/10.1177/1533317517698790
Tomaszewski S, Gauthier S, Wimo A, Rosa-Neto P (2016) Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer’s disease: socio-economic considerations modeled on treatments for tuberculosis, HIV/AIDS and breast cancer. J Prev Alzheimers Dis 3:164–172. https://doi.org/10.14283/jpad.2015.85
Raikwar SP, Thangavel R, Dubova I, Ahmed ME, Selvakumar PG, Kempuraj D et al (2018) Neuro-immuno-gene- and genome-editing-therapy for Alzheimer’s disease: are we there yet? J Alzheimers Dis 65(2):321–344. https://doi.org/10.3233/JAD-180422
Ahlawat J, Henriquez G, Narayan M (2018) Enhancing the delivery of chemotherapeutics: role of biodegradable polymeric nanoparticles. Molecules 23(9):2157. https://doi.org/10.3390/molecules23092157
Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A (2020) Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater 30(35):2003054. https://doi.org/10.1002/adfm.202003054
Indrit SEKO, Şahin A, Tonbul H, Çapan Y (2020) Brain-targeted nanoparticles to overcome the blood-brain barrier. J Pharm Technol 1(1):25–39. https://doi.org/10.37662/jpt.2020.4
Ghazy E, Rahdar A, Barani M, Kyzas GZ (2020) Nanomaterials for Parkinson disease: recent progress. J Mol Struct 129698. https://doi.org/10.1016/j.molstruc.2020.129698
Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ (2021) Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol 62:102426. https://doi.org/10.1016/j.jddst.2021.102426
Pathak K, Mishra SK, Porwal A, Bahadur S (2021) Nanocarriers for Alzheimer’s disease: research and patent update. J Appl Pharm Sci 11(3):001–021. https://doi.org/10.7324/JAPS.2021.110301
Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM (2010) Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(1):35–47. https://doi.org/10.1002/wnan.59
Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P (2014) Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano 8:76–103. https://doi.org/10.1021/nn405077y
Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B (2008) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res 1200:159–168. https://doi.org/10.1016/j.brainres.2008.01.039
Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm 59(2):263–272. https://doi.org/10.1016/j.ejpb.2004.07.009
Yang R, Zheng Y, Wang Q, Zhao L (2018) Curcumin-loaded chitosan-bovine serum albumin nanoparticles potentially enhanced Abeta 42 phagocytosis and modulated macrophage polarization in Alzheimer’s disease. Nanoscale Res Lett 13(1):330. https://doi.org/10.1186/s11671-018-2759-z
Baysal I, Ucar G, Gultekinoglu M, Ulubayram K, Yabanoglu-Ciftci S (2017) Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm (Vienna) 124(1):33–45. https://doi.org/10.1007/s00702-016-1527-4
Hanafy AS, Farid RM, Helmy MW, ElGamal SS (2016) Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management. Drug Deliv 23(8):3111–3122. https://doi.org/10.3109/10717544.2016.1153748
Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H et al (2018) Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int J Nanomedicine 13:705–718. https://doi.org/10.2147/IJN.S151474
Kaur S, Manhas P, Swami A, Bhandari R, Sharma KK, Jain R et al (2018) Bioengineered PLGA-chitosan nanoparticles for brain targeted intranasal delivery of antiepileptic TRH analogues. Chem Eng J 346:630–639. https://doi.org/10.1016/j.cej.2018.03.176
Fornaguera C, Feiner-Gracia N, Calderó G, García-Celma MJ, Solans C (2015) Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7(28):12076–12084. https://doi.org/10.1039/c5nr03474d
Aghamiri S, Noofeli M, Saffarian P, Salehi Najafabadi Z, Goudarzi HR (2022) Investigating preparation and characterisation of diphtheria toxoid-loaded on sodium alginate nanoparticles. IET Nanobiotechnol 16(5):199–209. https://doi.org/10.1049/nbt2.12088
Casadomé-Perales Á, Matteis L, Alleva M, Infantes-Rodríguez C, Palomares-Pérez I, Saito T et al (2019) Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules. Nanomedicine (Lond) 14(18):2409–2422. https://doi.org/10.2217/nnm-2018-0496
Fernandes J, Ghate MV, Basu Mallik S, Lewis SA (2018) Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor. Int J Pharm 547(1–2):563–571. https://doi.org/10.1016/j.ijpharm.2018.06.031
Jiang Z, Dong X, Sun Y (2018) Charge effects of self-assembled chitosan-hyaluronic acid nanoparticles on inhibiting amyloid β-protein aggregation. Carbohydrate Res 461:11–18. https://doi.org/10.1016/j.carres.2018.03.001
Cardia MC, Carta AR, Caboni P, Maccioni AM, Erbì S et al (2019) Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders. Pharmaceutics 11(12):657. https://doi.org/10.3390/pharmaceutics11120657
Kuo YC, Rajesh R (2017) Targeted delivery of rosmarinic acid across the blood-brain barrier for neuronal rescue using polyacrylamide-chitosan-poly(lactide-co-glycolide) nanoparticles with surface cross-reacting material 197 and apolipoprotein E. Int J Pharm 528(1–2):228–241. https://doi.org/10.1016/j.ijpharm.2017.05.039
Luo Q, Lin YX, Yang PP, Wang Y, Qi GB, Qiao ZY et al (2018) A self-destructive nanosweeper that captures and clears amyloid beta-peptides. Nat Commun 9(1):1802. https://doi.org/10.1038/s41467-018-04255-z
Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, Gavini E (2017) Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces 152:296–301. https://doi.org/10.1016/j.colsurfb.2017.01.031
Zameer S, Ali J, Vohora D, Najmi AK, Akhtar M (2021) Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer’s disease in intracerebroventricular streptozotocin model for brain delivery. J Drug Target 29(2):199–216. https://doi.org/10.1080/1061186X.2020.1817041
Doolaanea AA, Mansor N’, Mohd Nor NH, Mohamed F (2016) Co-encapsulation of Nigella sativa oil and plasmid DNA for enhanced gene therapy of Alzheimer’s disease. J Microencapsul 33(2):114–126.https://doi.org/10.3109/02652048.2015.1134689
Zhang X, Zhong M, Zhao P, Zhang X, Li Y, Wang X et al (2019) Screening a specific Zn(ii)-binding peptide for improving the cognitive decline of Alzheimer’s disease in APP/PS1 transgenic mice by inhibiting Zn2+-mediated amyloid protein aggregation and neurotoxicity. Biomater Sci 7(12):5197–5210. https://doi.org/10.1039/c9bm00676a
Vicente-Zurdo D, Romero-Sánchez I, Rosales-Conrado N, León-González ME, Madrid Y (2020) Ability of selenium species to inhibit metal-induced Aβ aggregation involved in the development of Alzheimer’s disease. Anal Bioanal Chem 412(24):6485–6497. https://doi.org/10.1007/s00216-020-02644-2
Su W, Xu W, Liu E, Su W, Polyakov NE (2023) Improving the treatment effect of carotenoids on Alzheimer’s disease through various nano-delivery systems. Int J Mol Sci 24(8):7652. https://doi.org/10.3390/ijms24087652
Hassan N, Cordero ML, Sierpe R, Almada M, Juárez J, Valdez M et al (2018) Peptide functionalized magneto-plasmonic nanoparticles obtained by microfluidics for inhibition of β-amyloid aggregation. J Mater Chem B 6:5091–5099. https://doi.org/10.1039/C8TB00206A
Topal GR, Mészáros M, Porkoláb G, Szecskó A, Polgár TF, Siklós L et al (2021) ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood–brain barrier. Pharmaceutics 13(1):38. https://doi.org/10.3390/pharmaceutics13010038
Zhang H, Zhao Y, Yu M, Zhao Z, Liu P, Cheng H et al (2019) Reassembly of native components with donepezil to execute dual-missions in Alzheimer’s disease therapy. J Control Release 296:14–28. https://doi.org/10.1016/j.jconrel.2019.01.008
Fernández-de-Retana S, Cano-Sarabia M, Marazuela P, Sánchez-Quesada JL, Garcia-Leon A, Montañola A et al (2017) Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis. Sci Rep 7(1):14637. https://doi.org/10.1038/s41598-017-15215-w
Dos Santos RB, Kanekiyo T, Singh J (2019) ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res 36(11):161. https://doi.org/10.1007/s11095-019-2691-7
Song Q, Song H, Xu J, Huang J, Hu M, Gu X et al (2016) Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery. Mol Pharm 13(11):3976–3987. https://doi.org/10.1021/acs.molpharmaceut.6b00781
Gutiérrez-Carcedo P, Navalón S, Simó R, Setoain X, Aparicio-Gómez C, Abasolo I et al (2020) Alteration of the mitochondrial effects of ceria nanoparticles by gold: an approach for the mitochondrial modulation of cells based on nanomedicine. Nanomaterials 10(4):744. https://doi.org/10.3390/nano10040744
Sharma N, Banerjee R, Davis RL (2023) Early mitochondrial defects in the 5xFAD mouse model of Alzheimer’s disease. J Alzheimers Dis 91(4):1323–1338. https://doi.org/10.3233/JAD-220884
Kim D, Kwon HJ, Hyeon T (2019) Magnetite/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-β in Alzheimer’s disease. Adv Mater 31(19):e1807965. https://doi.org/10.1002/adma.201807965
Huang Y, Chang Y, Liu L, Wang J (2021) Nanomaterials for modulating the aggregation of β-amyloid peptides. Molecules 26(14):4301. https://doi.org/10.3390/molecules26144301
Yu D, Ma M, Liu Z, Pi Z, Du X, Ren J, Qu X (2020) MOF-encapsulated nanozyme enhanced siRNA combo: control neural stem cell differentiation and ameliorate cognitive impairments in Alzheimer’s disease model. Biomaterials 255:120160. https://doi.org/10.1016/j.biomaterials.2020.120160
Karimzadeh M, Rashidi L, Ganji F (2017) Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 43(4):628–636. https://doi.org/10.1080/03639045.2016.1275668
Yang X, He C, Li J, Chen H, Ma Q, Sui X et al (2014) Uptake of silica nanoparticles: neurotoxicity and Alzheimer-like pathology in human SK-N-SH and mouse neuro2a neuroblastoma cells. Toxicol Lett 229(1):240–249. https://doi.org/10.1016/j.toxlet.2014.05.009
Halevas E, Nday CM, Salifoglou A (2016) Hybrid catechin silica nanoparticle influence on Cu(II) toxicity and morphological lesions in primary neuronal cells. J Inorg Biochem 163:240–249. https://doi.org/10.1016/j.jinorgbio.2016.04.017
Xu Y, Zhao M, Zhou D, Zheng T, Zhang H (2021) The application of multifunctional nanomaterials in Alzheimer’s disease: a potential theranostics strategy. Biomed Pharmacother 137:111360. https://doi.org/10.1016/j.biopha.2021.111360
Nday CM, Halevas E, Jackson GE, Salifoglou A (2015) Quercetin encapsulation in modified silica nanoparticles: potential use against Cu(II)-induced oxidative stress in neurodegeneration. J Inorg Biochem 145:51–64. https://doi.org/10.1016/j.jinorgbio.2015.01.001
Nday CM, Eleftheriadou D, Jackson G (2019) Magnetic chrysin silica nanomaterials behavior in an amyloidogenic environment. Hell J Nucl Med 22:42–50
Yang L, Yin T, Liu Y, Sun J, Zhou Y, Liu J (2016) Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer’s disease treatment. Acta Biomater 46:177–190. https://doi.org/10.1016/j.actbio.2016.09.010
Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK (2018) Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv 25(1):307–320. https://doi.org/10.1080/10717544.2018.1428243
Matias AC, Matos J, Dohmen RJ, Ramos PC (2023) Hsp70 and Hsp110 chaperones promote early steps of proteasome assembly. Biomolecules 13(1):11. https://doi.org/10.3390/biom13010011
Wang H, Muiznieks LD, Ghosh P, Williams D, Solarski M, Fang A et al (2017) Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers. Elife 6:e28401. https://doi.org/10.7554/eLife.28401
Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, Hureau C (2011) Iron(II) binding to amyloid-β, the Alzheimer’s peptide. Inorg Chem 50(18):9024–9030. https://doi.org/10.1021/ic201233b
Agrawal M, Ajazuddin TDK, Saraf S, Saraf S, Antimisiaris SG et al (2017) Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s disease. J Control Release 260:61–77. https://doi.org/10.1016/j.jconrel.2017.05.019
Ross C, Taylor M, Fullwood N, Allsop D (2018) Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 13:8507–8522. https://doi.org/10.2147/IJN.S183117
Kuo YC, Chen CL, Rajesh R (2019) Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. Acta Biomater 87:207–222. https://doi.org/10.1016/j.actbio.2019.01.065
Dos Santos RB, Lakkadwala S, Kanekiyo T, Singh J (2019) Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomedicine 14:6497–6517. https://doi.org/10.2147/IJN.S215941
Sun X, Chen Y, Zhao H, Qiao G, Liu M, Zhang C et al (2018) Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma. Drug Deliv 25(1):1718–1727. https://doi.org/10.1080/10717544.2018
Bender HR, Kane S, Zabel MD (2016) Delivery of therapeutic siRNA to the CNS using cationic and anionic liposomes. J Vis Exp 113:54106. https://doi.org/10.3791/54106
Ha D, Yang N, Nadithe V (2016) Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 6(4):287–296. https://doi.org/10.1016/j.apsb.2016.02.001
Simons M, Raposo G (2009) Exosomes—vesicular carriers for intercellular communication. Curr Opin Cell Biol 21(4):575–581. https://doi.org/10.1016/j.ceb.2009.03.007
Chung IM, Rajakumar G, Venkidasamy B, Subramanian U, Thiruvengadam M (2020) Exosomes: current use and future applications. Clin Chim Acta 500:226–232. https://doi.org/10.1016/j.cca.2019.10.022
Johnstone RM (2005) Revisiting the road to the discovery of exosomes. Blood Cells Mol Dis 34(3):214–219. https://doi.org/10.1016/j.bcmd.2005.03.002
Qin J, Xu Q (2014) Functions and application of exosomes. Acta Pol Pharm 71(4):537–543
Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83–98. https://doi.org/10.1016/S1474-4422(10)70245-3
(1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72(6):971–83. https://doi.org/10.1016/0092-8674(93)90585-e
Sah DW, Aronin N (2011) Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 121(2):500–507. https://doi.org/10.1172/JCI45130
Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K et al (2016) Exosome-mediated delivery of hydrophobically modified siRNA for Huntingtin mRNA silencing. Mol Ther 24(10):1836–1847. https://doi.org/10.1038/mt.2016.126
Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S et al (2008) In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener 3:19. https://doi.org/10.1186/1750-1326-3-19
Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M et al (2014) Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord 29(12):1476–1485. https://doi.org/10.1002/mds.25978
Bramlett HM, Dietrich WD (2015) Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma 32(23):1834–1848. https://doi.org/10.1089/neu.2014.3352
Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS (2012) Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 10:5. https://doi.org/10.1186/1479-5876-10-5
Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 179(3):1913–1925. https://doi.org/10.4049/jimmunol.179.3.1913
de Rivero Vaccari JP, Brand F, Adamczak S, Lee SW, Perez-Barcena J, Wang MY et al (2016) Exosome-mediated inflammasome signaling after central nervous system injury. J Neurochem 136(Suppl 1):39–48. https://doi.org/10.1111/jnc.13036
Lai RC, Yeo RW, Lim SK (2015) Mesenchymal stem cell exosomes. Semin Cell Dev Biol 40:82–88. https://doi.org/10.1016/j.semcdb.2015.03.001
Bonafede R, Scambi I, Peroni D, Potrich V, Boschi F, Benati D et al (2016) Exosome derived from murine adipose-derived stromal cells: neuroprotective effect on in vitro model of amyotrophic lateral sclerosis. Exp Cell Res 340(1):150–158. https://doi.org/10.1016/j.yexcr.2015.12.009
Hu G, Liao K, Niu F, Yang L, Dallon BW et al (2018) Astrocyte EV-induced lincRNA-Cox2 regulates microglial phagocytosis: implications for morphine-mediated neurodegeneration. Mol Ther Nucleic Acids 13:450–463. https://doi.org/10.1016/j.omtn.2018.09.019
Ren X, Zhao Y, Xue F, Zheng Y, Huang H, Wang W et al (2019) Exosomal DNA aptamer targeting alpha-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson’s disease model. Mol Ther Nucleic Acids 17:726–740. https://doi.org/10.1016/j.omtn.2019.07.008
So S, Lodge TP (2016) Size control and fractionation of ionic liquid filled polymersomes with glassy and rubbery bilayer membranes. Langmuir 32(19):4959–4968. https://doi.org/10.1021/acs.langmuir.6b00946
Leeand JS, Feijen J (2012) Polymersomes for drug delivery: design, formation and characterization. J Control Release 161(2):473–483. https://doi.org/10.1016/j.jconrel.2011.10.005
Jia T, Sun Z, Lu Y, Gao J, Zou H, Xie F et al (2016) A dual brain-targeting curcumin-loaded polymersomes ameliorated cognitive dysfunction in intrahippocampal amyloid-beta1-42-injected mice. Int J Nanomedicine 11:3765–3775. https://doi.org/10.2147/IJN.S94622
Kandil R, Merkel OM (2019) Recent progress of polymeric nanogels for gene delivery. Curr Opin Colloid Interface Sci 39:11–23. https://doi.org/10.1016/j.cocis.2019.01.005
Almutairi MCA (2016) Nanogels as imaging agents for modalities spanning the electromagnetic spectrum. Mater Horiz 3(1):21–40. https://doi.org/10.1039/c5mh00161g
Chen W, Zou Y, Zhong Z, Haag R (2017) Cyclo(RGD)-decorated reduction-responsive nanogels mediate targeted chemotherapy of integrin overexpressing human glioblastoma in vivo. Small 13(6). https://doi.org/10.1002/smll.201601997
Tsao CT, Kievit FM, Ravanpay A, Erickson AE, Jensen MC (2014) Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacromol 15(7):2656–2662. https://doi.org/10.1021/bm500502n
Bi Y, Yang X, Zhang T, Liu Z, Zhang X, Lu J et al (2015) Design, synthesis, nitric oxide release and antibacterial evaluation of novel nitrated ocotillol-type derivatives. Eur J Med Chem 101:71–80. https://doi.org/10.1016/j.ejmech.2015.06.021
Song B, Song J, Zhang S, Anderson MA, Ao Y, Yang CY et al (2012) Sustained local delivery of bioactive nerve growth factor in the central nervous system via tunable diblock copolypeptide hydrogel depots. Biomaterials 33(35):9105–9116. https://doi.org/10.1016/j.biomaterials.2012.08.060
Aderibigbe BA, Naki T (2018) Design and efficacy of nanogels formulations for intranasal administration. Molecules 23(6). https://doi.org/10.3390/molecules23061241
Kim B, Feldman EL (2015) Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med 47:e149. https://doi.org/10.1038/emm.2015.3
Picone P, Sabatino MA, Ditta LA, Amato A, San Biagio PL, Mule F et al (2018) Nose-to-brain delivery of insulin enhanced by a nanogel carrier. J Control Release 270:23–36. https://doi.org/10.1016/j.jconrel.2017.11.040
Picone P, Ditta LA, Sabatino MA, Militello V, San Biagio PL et al (2016) Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer’s disease. Biomaterials 80:179–194. https://doi.org/10.1016/j.biomaterials.2015.11.057
Elnaggar YSR, Etman SM, Abdelmonsif DA, Abdallah OY (2015) Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104(10):3544–3556. https://doi.org/10.1002/jps.24557
Baltzley S, Mohammad A, Malkawi AH, Al-Ghananeem AM (2014) Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles. AAPS PharmSci Tech 15(6):1598–1602. https://doi.org/10.1208/s12249-014-0189-5
Hu KL, Mei N, Feng L, Jiang XG (2009) Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: improved bioavailability and brain delivery in rats with low ciliotoxicity. Arzneimittelforschung 59(12):635–640. https://doi.org/10.1055/s-0031-1296452
Haque S, Md S, Sahni JK, Ali J, Baboota S (2014) Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 48(1):1–12. https://doi.org/10.1016/j.jpsychires.2013.10.011
Tonda-Turo C, Herva M, Chiono V, Ciardelli G, Spillantini MG (2018) Influence of drug-carrier polymers on alpha-synucleinopathies: a neglected aspect in new therapies development. Biomed Res Int 2018:4518060
Cook DJ, Nguyen C, Chun HN, Llorente IL, Chiu AS, Machnicki M et al (2017) Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. J Cereb Blood Flow Metab 37(3):1030–1045. https://doi.org/10.1177/0271678X16649964
Zhang S, Anderson MA, Ao Y, Khakh BS, Fan J, Deming TJ, Sofroniew MV (2014) Tunable diblock copolypeptide hydrogel depots for local delivery of hydrophobic molecules in healthy and injured central nervous system. Biomaterials 35(6):1989–2000. https://doi.org/10.1016/j.biomaterials.2013.11.005
Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P (1996) Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci U S A 93(20):10887–10890. https://doi.org/10.1073/pnas.93.20.10887
Kumar P, Wu H, McBride JL, Jung KE, Kim MH et al (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43. https://doi.org/10.1038/nature05901
Gao Y, Wang ZY, Zhang J, Zhang Y, Huo H, Wang T et al (2014) RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromol 15(3):1010–1018. https://doi.org/10.1021/bm401906p
Schulze J, Hendrikx S, Schulz-Siegmund M, Aigner A (2016) Microparticulate poly(vinyl alcohol) hydrogel formulations for embedding and controlled release of polyethylenimine (PEI)-based nanoparticles. Acta Biomater 45:210–222. https://doi.org/10.1016/j.actbio.2016.08.056
Höbel S, Aigner A (2013) Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 5(5):484–501. https://doi.org/10.1002/wnan.1228
Shi LL, Lu J, Cao Y, Liu JY, Zhang XX, Zhang H et al (2017) Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel. Drug Dev Ind Pharm 43(5):839–846. https://doi.org/10.1080/03639045.2016.1220571
Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C et al (2017) Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules 22(2):277. https://doi.org/10.3390/molecules22020277
Montenegro L, Turnaturi R, Parenti C, Pasquinucci L (2018) Idebenone: novel strategies to improve its systemic and local efficacy. Nanomaterials 8(2):87. https://doi.org/10.3390/nano8020087
Montenegro L, Panico AM, Santagati LM, Siciliano EA, Intagliata S, Modica MN (2018) Solid lipid nanoparticles loading idebenone ester with pyroglutamic acid: in vitro antioxidant activity and in vivo topical efficacy. Nanomaterials 9(1):43. https://doi.org/10.3390/nano9010043
Stockley JH, Ravid R, O’Neill C (2006) Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer’s disease brain. FEBS Lett 580(28–29):6550–6560. https://doi.org/10.1016/j.febslet.2006.10.076
Erel-Akbaba G, Carvalho LA, Tian T, Zinter M, Akbaba H, Obeid PJ (2019) Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano 13(4):4028–4040. https://doi.org/10.1021/acsnano.8b08177
Li X, Lian Z, Wang S, Xing L, Yu J (2018) Interactions between EGFR and PD-1/PD-L1 pathway: implications for treatment of NSCLC. Cancer Lett 418:1–9. https://doi.org/10.1016/j.canlet.2018.01.005
Bogdanowich-Knipp SJ, Jois DS, Siahaan TJ (1999) The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J Pept Res 53(5):523–9. https://doi.org/10.1034/j.1399-3011.1999.00055.x
Scuteri D, Sakurada S, Sakurada T, Tonin P, Bagetta G, Nicotera P, Corasaniti MT (2022) Requirements for translation in clinical trials of aromatherapy: the case of the essential oil of bergamot (BEO) for management of agitation in severe dementia. Curr Pharm Des 28(20):1607–1610. https://doi.org/10.2174/1381612828666220509152029
Haensler J, Szoka FC Jr (1993) Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 4(5):372–379. https://doi.org/10.1021/bc00023a012
Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW et al (2014) Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett 9(1):247. https://doi.org/10.1186/1556-276X-9-247
Khan OF, Zaia EW, Yin H, Bogorad RL, Pelet JM, Webber MJ (2014) Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew Chem Int Ed Engl 53(52):14397–14401. https://doi.org/10.1002/anie.201408221
Liu X, Li G, Su Z, Jiang Z, Chen L, Wang J, Yu S, Liu Z (2013) Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol Rep 29(4):1387–1394. https://doi.org/10.3892/or.2013.2283
Igartua DE, Martinez CS, Temprana CF, Alonso SDV, Prieto MJ (2018) PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: a biophysical and nanotoxicological characterization. Int J Pharm 544(1):191–202. https://doi.org/10.1016/j.ijpharm.2018.04.032
Qiu J, Kong L, Cao X, Li A, Wei P, Wang L et al (2018) Enhanced delivery of therapeutic siRNA into glioblastoma cells using dendrimer-entrapped gold nanoparticles conjugated with β-cyclodextrin. Nanomaterials 8(3):131. https://doi.org/10.3390/nano8030131
Szwed A, Miłowska K, Michlewska S, Moreno S, Shcharbin D, Gomez-Ramirez R et al (2020) Generation dependent effects and entrance to mitochondria of hybrid dendrimers on normal and cancer neuronal cells in vitro. Biomolecules 10(3):427. https://doi.org/10.3390/biom10030427
Bae Y, Thuy LT, Lee YH, Ko KS, Han J, Choi JS (2019) Polyplexes of functional PAMAM dendrimer/apoptin gene induce apoptosis of human primary glioma cells in vitro. Polymers 11(2):296. https://doi.org/10.3390/polym11020296
Abourehab MA, Ahmed OA, Balata GF, Almalki WH (2018) Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood-brain barrier. Int J Nanomedicine 13:3679–3687. https://doi.org/10.2147/IJN.S168148
Mandracchia D, Tripodo G, Latrofa A, Dorati R (2014) Amphiphilic inulin-D-α-tocopherol succinate (INVITE) bioconjugates for biomedical applications. Carbohydr Polym 103:46–54. https://doi.org/10.1016/j.carbpol.2013.11.056
Tripodo G, Chlapanidas T, Perteghella S, Vigani B, Mandracchia D, Trapani A et al (2015) Mesenchymal stromal cells loading curcumin-INVITE-micelles: a drug delivery system for neurodegenerative diseases. Colloids Surf B Biointerfaces 125:300–308. https://doi.org/10.1016/j.colsurfb.2014.11.034
Yoon JY, Yang KJ, Park SN, Kim DK, Kim JD (2016) The effect of dexamethasone/cell-penetrating peptide nanoparticles on gene delivery for inner ear therapy. Int J Nanomedicine 11:6123–6134. https://doi.org/10.2147/IJN.S114241
Priya James H, John R, Alex A, Anoop KR (2014) Smart polymers for the controlled delivery of drugs - a concise overview. Acta Pharm Sin B 4(2):120–127. https://doi.org/10.1016/j.apsb.2014.02.005
Peng Y, Huang J, Xiao H, Wu T, Shuai X (2018) Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment. Int J Nanomedicine 13:3467–3480. https://doi.org/10.2147/IJN.S164611
Shi H, Sun S, Xu H, Zhao Z, Han Z, Jia J, Wu D, Lu J et al (2020) Combined delivery of temozolomide and siPLK1 using targeted nanoparticles to enhance temozolomide sensitivity in glioma. Int J Nanomedicine 15:3347–3362. https://doi.org/10.2147/IJN.S243878
Wang X, Hua Y, Xu G, Deng S, Yang D, Gao X (2019) Targeting EZH2 for glioma therapy with a novel nanoparticle-siRNA complex. Int J Nanomedicine 14:2637–2653. https://doi.org/10.2147/IJN.S189871
Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ (2015) EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520(7546):239–242. https://doi.org/10.1038/nature14122
Kafa H, Wang JT, Rubio N, Klippstein R, Costa PM, Hassan HA et al (2016) Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo. J Control Release 225:217–229. https://doi.org/10.1016/j.jconrel.2016.01.031
Bertrand Y, Currie JC, Poirier J, Demeule M, Abulrob A, Fatehi D et al (2011) Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer 105(11):1697–1707. https://doi.org/10.1038/bjc.2011.427
Turek A, Olakowska E, Borecka A, Janeczek H, Sobota M, Jaworska J et al (2016) Shape-memory terpolymer rods with 17-β-estradiol for the treatment of neurodegenerative diseases: an in vitro and in vivo study. Pharm Res 33(12):2967–2978. https://doi.org/10.1007/s11095-016-2019-9
Francis NL, Bennett NK, Halikere A, Pang ZP, Moghe PV (2016) Self-assembling peptide nanofiber scaffolds for 3-D reprogramming and transplantation of human pluripotent stem cell-derived neurons. ACS Biomater Sci Eng 2(6):1030–1038. https://doi.org/10.1021/acsbiomaterials.6b00156
Lin G, Wang X, Yin F, Yong KT (2015) Passive tumor targeting and imaging by using mercaptosuccinic acid-coated near-infrared quantum dots. Int J Nanomedicine 10:335–345. https://doi.org/10.2147/IJN.S74805
Smith AM, Duan H, Mohs AM, Nie S (2008) Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev 60(11):1226–1240. https://doi.org/10.1016/j.addr.2008.03.015
Wang Y, Leck KS, Ta VD, Chen R, Nalla V, Gao Y et al (2015) Blue liquid lasers from solution of CdZnS/ZnS ternary alloy quantum dots with quasi-continuous pumping. Adv Mater 27(1):169–175. https://doi.org/10.1002/adma.201403237
He X, Ma N (2014) An overview of recent advances in quantum dots for biomedical applications. Colloids Surf B Biointerfaces 124:118–131. https://doi.org/10.1016/j.colsurfb.2014.06.002
Balan AD, Eshet H, Olshansky JH, Lee YV, Rabani E, Alivisatos AP (2017) Effect of thermal fluctuations on the radiative rate in core/shell quantum dots. Nano Lett 17(3):1629–1636. https://doi.org/10.1021/acs.nanolett.6b04816
Yang HY, Fu Y, Jang MS, Li Y, Yin WP, Ahn TK (2017) CdSe@ZnS/ZnS quantum dots loaded in polymeric micelles as a pH-triggerable targeting fluorescence imaging probe for detecting cerebral ischemic area. Colloids Surf B Biointerfaces 155:497–506. https://doi.org/10.1016/j.colsurfb.2017.04.054
Lin G, Chen T, Zou J, Wang Y, Wang X, Li J, Huang Q, Fu Z et al (2017) Quantum dots-siRNA nanoplexes for gene silencing in central nervous system tumor cells. Front Pharmacol 8:182. https://doi.org/10.3389/fphar.2017.00182
Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong KT et al (2009) MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 1282:142–155. https://doi.org/10.1016/j.brainres.2009.05.047
Getz T, Qin J, Medintz IL, Delehanty JB, Susumu K, Dawson PE, Dawson G (2016) Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells. J Neurochem 139(5):872–885. https://doi.org/10.1111/jnc.13841
Walters R, Medintz IL, Delehanty JB, Stewart MH, Susumu K, Huston AL et al (2015) The role of negative charge in the delivery of quantum dots to neurons. ASN Neuro 7(4):1759091415592389. https://doi.org/10.1177/1759091415592389
Algar WR, Susumu K, Delehanty JB, Medintz IL (2011) Semiconductor quantum dots in bioanalysis: crossing the valley of death. Anal Chem 83(23):8826–8837. https://doi.org/10.1021/ac201331r
NCT03806478 (2023) https://classic.clinicaltrials.gov/ct2/show/NCT03806478. Accessed 29 June 2023
Osterhage JL, Friedman KL (2009) Chromosome end maintenance by telomerase. J Biol Chem 284(24):16061–16065. https://doi.org/10.1074/jbc.R900011200
Kaushik NK, Kaushik N, Wahab R, Bhartiya P, Linh NN, Khan F et al (2020) Cold atmospheric plasma and gold quantum dots exert dual cytotoxicity mediated by the cell receptor-activated apoptotic pathway in glioblastoma cells. Cancers 12(2):457. https://doi.org/10.3390/cancers12020457
Kumarasamy M, Sosnik A (2021) Heterocellular spheroids of the neurovascular blood-brain barrier as a platform for personalized nanoneuromedicine. iScience 24(3):102183. https://doi.org/10.1016/j.isci.2021.102183
Marcuzzo S, Isaia D, Bonanno S, Malacarne C, Cavalcante P, Zacheo A et al (2019) FM19G11-loaded gold nanoparticles enhance the proliferation and self-renewal of ependymal stem progenitor cells derived from ALS mice. Cells 8(3):279. https://doi.org/10.3390/cells8030279
Park SY, Yi EH, Kim Y, Park G (2019) Anti-neuroinflammatory effects of Ephedra sinica Stapf extract-capped gold nanoparticles in microglia. Int J Nanomedicine 14:2861–2877. https://doi.org/10.2147/IJN.S195218
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70(1–2):1–20. https://doi.org/10.1016/s0168-3659(00)00339-4
Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O (2009) Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 26(5):427–521. https://doi.org/10.1615/critrevtherdrugcarriersyst.v26.i5.10
Zhang L, Wang S, Zhang M, Sun J (2013) Nanocarriers for oral drug delivery. J Drug Target 21(6):515–527. https://doi.org/10.3109/1061186X.2013.789033
Kotta S, Khan AW, Pramod K, Ansari SH, Sharma RK, Ali J (2012) Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 9(5):585–598. https://doi.org/10.1517/17425247.2012.668523
Gaba B, Khan T, Haider MF, Alam T, Baboota S, Parvez S, Ali J (2019) Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model. Biomed Res Int 2019:2382563. https://doi.org/10.1155/2019/2382563
Cunha A, Prévot G, Mousli Y, Barthélémy P, Crauste-Manciet S, Dehay B, Desvergnes V (2020) Synthesis and intracellular uptake of rhodamine-nucleolipid conjugates into a nanoemulsion vehicle. ACS Omega 5(11):5815–5823. https://doi.org/10.1021/acsomega.9b03992
Mirza A, Rathore MH (2012) Human immunodeficiency virus and the central nervous system. Semin Pediatr Neurol 19(3):119–123. https://doi.org/10.1016/j.spen.2012.02.007
Yadav S, Gandham SK, Panicucci R, Amiji MM (2016) Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation. Nanomedicine 12(4):987–1002. https://doi.org/10.1016/j.nano.2015.12.374
Gwak SJ, Yun Y, Yoon DH, Kim KN, Ha Y (2016) Therapeutic use of 3beta-[N-(Nʹ, Nʹ-dimethylaminoethane) carbamoyl] cholesterol-modified PLGA nanospheres as gene delivery vehicles for spinal cord injury. PLoS ONE 11(1):e0147389. https://doi.org/10.1371/journal.pone.0147389
Osterlund N, Kulkarni YS, Misiaszek AD, Wallin C, Kruger DM, Liao Q et al (2018) Amyloid-beta peptide interactions with amphiphilic surfactants: electrostatic and hydrophobic effects. ACS Chem Neurosci 9(7):1680–1692. https://doi.org/10.1021/acschemneuro.8b00065
Agazzi ML, Herrera SE, Cortez ML, Marmisollé WA, Tagliazucchi M, Azzaroni O (2020) Insulin delivery from glucose-responsive, self-assembled, polyamine nanoparticles: smart “sense-and-treat” nanocarriers made easy. Chemistry 26(11):2456–2463. https://doi.org/10.1002/chem.201905075
Kose T, Vera-Aviles M, Sharp PA, Latunde-Dada GO (2019) Curcumin and (−)- Epigallocatechin-3-gallate protect murine MIN6 pancreatic beta-cells against iron toxicity and erastin-induced ferroptosis. Pharmaceuticals (Basel) 12(1):26. https://doi.org/10.3390/ph12010026
Chierchia A, Chirico N, Boeri L, Raimondi I, Riva GA, Raimondi MT et al (2017) Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson’s disease related toxin 6-hydroxydopamine. Eur J Pharm Biopharm 121:113–120. https://doi.org/10.1016/j.ejpb.2017.09.014
Naser SS, Singh D, Preetam S, Kishore S, Kumar L, Nandi A et al (2023) Posterity of nanoscience as lipid nanosystems for Alzheimer’s disease regression. Mater Today Bio 21:100701. https://doi.org/10.1016/j.mtbio.2023.100701
Dos Santos RB, Lakkadwala S, Kanekiyo T, Singh J (2020) Dual-modified liposome for targeted and enhanced gene delivery into mice brain. J Pharmacol Exp Ther 374(3):354–365. https://doi.org/10.1124/jpet.119.264127
Alzhrani R, Alsaab HO, Petrovici A, Bhise K, Vanamala K, Sau S, Krinock MJ, Iyer AK (2020) Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems. Drug Discov Today 25(4):718–730. https://doi.org/10.1016/j.drudis.2019.11.006
Chen Z, Liu F, Chen Y, Liu J, Wang X, Chen AT et al (2017) Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles. Adv Funct Mater 27(46):1703036. https://doi.org/10.1002/adfm.201703036
Huang L, Tang H, Sherchan P, Lenahan C, Boling W, Tang J, Zhang JH (2020) The activation of phosphatidylserine/CD36/TGF-β1 pathway prior to surgical brain injury attenuates neuroinflammation in rats. Oxid Med Cell Longev 2020:4921562. https://doi.org/10.1155/2020/4921562
Rakotoarisoa M, Angelova A (2018) Amphiphilic nanocarrier systems for curcumin delivery in neurodegenerative disorders. Medicines (Basel) 5(4):126. https://doi.org/10.3390/medicines5040126
Shariare MH, Rahman M, Lubna SR, Roy RS, Abedin J, Marzan AL et al (2020) Liposomal drug delivery of Aphanamixis polystachya leaf extracts and its neurobehavioral activity in mice model. Sci Rep 10(1):6938. https://doi.org/10.1038/s41598-020-63894-9
Platania CBM, Fisichella V, Fidilio A, Geraci F, Lazzara F, Leggio GM (2017) Topical ocular delivery of TGF-β1 to the back of the eye: implications in age-related neurodegenerative diseases. Int J Mol Sci 18(10):2076. https://doi.org/10.3390/ijms18102076
Rodriguez-Izquierdo I, Serramia MJ, Gomez R, De La Mata FJ, Bullido MJ, Ma MF (2020) Gold nanoparticles crossing blood-brain barrier prevent HSV-1 infection and reduce herpes associated amyloid-β secretion. J Clin Med 9(1):155. https://doi.org/10.3390/jcm9010155
Cheng CH, Lin KJ, Hong CT, Wu D, Chang HM, Liu CH et al (2019) Plasmon-activated water reduces amyloid burden and improves memory in animals with Alzheimer’s disease. Sci Rep 9(1):13252. https://doi.org/10.1038/s41598-019-49731-8
Liu D, Li W, Jiang X, Bai S, Liu J, Liu X et al (2019) Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer’s disease. Theranostics 9(8):2268–2281. https://doi.org/10.7150/thno.30649
Mujeeb AA, Alam KFB, Alshameri AWF, Jamal F, Farheen S, Kashif M et al (2019) Chaperone like attributes of biogenic fluorescent gold nanoparticles: potential to alleviate toxicity induced by intermediate state fibrils against neuroblastoma cells. Front Chem 7:787. https://doi.org/10.3389/fchem.2019.00787
Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T et al (2013) Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis 12:68. https://doi.org/10.1186/1476-511X-12-68
Pokharkar V, Suryawanshi S, Dhapte-Pawar V (2020) Exploring micellar-based polymeric systems for effective nose-to-brain drug delivery as potential neurotherapeutics. Drug Deliv Transl Res 10(4):1019–1031. https://doi.org/10.1007/s13346-019-00702-6
Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y (2013) Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 34(36):9220–9226. https://doi.org/10.1016/j.biomaterials.2013.08.036
Loureiro JA, Gomes B, Fricker G, Coelho MAN, Rocha S, Pereira MC (2016) Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment. Colloids Surf B Biointerfaces 145:8–13. https://doi.org/10.1016/j.colsurfb.2016.04.041
Vakilinezhad MA, Amini A, Akbari Javar H, Baha’addini Beigi Zarandi BF, Montaseri H, Dinarvand R (2018) Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation. Daru 26(2):165–177. https://doi.org/10.1007/s40199-018-0221-5
Polchi A, Magini A, Mazuryk J, Tancini B, Gapiński J, Patkowski A et al (2016) Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: formulation and in vitro characterization. Nanomaterials (Basel) 6(5):87. https://doi.org/10.3390/nano6050087
Jiang Y, Liu C, Zhai W, Zhuang N, Han T, Ding Z (2019) The optimization design of lactoferrin loaded HupA nanoemulsion for targeted drug transport via intranasal route. Int J Nanomedicine 14:9217–9234. https://doi.org/10.2147/IJN.S214657
Lima AF, Amado IR, Pires LR (2020) Poly(d, l-lactide-co-glycolide) (PLGA) nanoparticles loaded with proteolipid protein (PLP)-exploring a new administration route. Polymers (Basel) 12(12):3063. https://doi.org/10.3390/polym12123063
Del Amo L, Cano A, Ettcheto M, Souto EB, Espina M et al (2021) Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer’s disease. Appl Sci 11(9):4305. https://doi.org/10.3390/app11094305
Fan S, Zheng Y, Liu X, Fang W, Chen X, Liao W et al (2018) Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv 25(1):1091–1102. https://doi.org/10.1080/10717544.2018.1461955
Cano A, Ettcheto M, Chang JH, Barroso E, Espina M, Kühne BA et al (2019) Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model. J Control Release 301:62–75. https://doi.org/10.1016/j.jconrel.2019.03.010
Park EK, Kim SY, Lee SB, Lee YM (2005) Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 109(1–3):158–168. https://doi.org/10.1016/j.jconrel.2005.09.039
Shao K, Huang R, Li J, Han L, Ye L, Lou J, Jiang C (2010) Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 147(1):118–126. https://doi.org/10.1016/j.jconrel.2010.06.018
Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J et al (2013) Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2(12):e136. https://doi.org/10.1038/mtna.2013.65
Gorshkov A, Purvinsh L, Brodskaia A, Vasin A (2022) Exosomes as natural nanocarriers for RNA-based therapy and prophylaxis. Nanomaterials 12(3):524. https://doi.org/10.3390/nano12030524
Pan R, Chen D, Hou L, Hu R, Jiao Z (2023) Small extracellular vesicles: a novel drug delivery system for neurodegenerative disorders. Front Aging Neurosci 15:1184435. https://doi.org/10.3389/fnagi.2023.1184435
Liu W, He Z, Liang J, Zhu Y, Xu H, Yang X (2008) Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mater Res A 84(4):1018–1025. https://doi.org/10.1002/jbm.a.31205
Bae KH, Lee JY, Lee SH, Park TG, Nam YS (2013) Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv Healthc Mater 2(4):576–584. https://doi.org/10.1002/adhm.201200338
Kim D, Yoo JM, Hwang H, Lee J, Lee SH, Yun SP et al (2018) Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease. Nat Nanotechnol 13(9):812–818. https://doi.org/10.1038/s41565-018-0179-y
Scioli Montoto S, Sbaraglini ML, Talevi A, Couyoupetrou M, Di Ianni M, Pesce GO et al (2018) Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces 167:73–81. https://doi.org/10.1016/j.colsurfb.2018.03.052
Gamage NH, Jing L, Worsham MJ, Ali MM (2016) Targeted theranostic approach for glioma using dendrimer-based curcumin nanoparticle. J Nanomed Nanotechnol 7(4):393. https://doi.org/10.4172/2157-7439.1000393
Jiang Y, Lv L, Shi H, Hua Y, Lv W, Wang X et al (2016) PEGylated polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma. Colloids Surf B Biointerfaces 147:242–249. https://doi.org/10.1016/j.colsurfb.2016.08.002
Stenström P, Manzanares D, Zhang Y, Ceña V, Malkoch M (2018) Evaluation of amino-functional polyester dendrimers based on Bis-MPA as nonviral vectors for siRNA delivery. Molecules 23(8):2028. https://doi.org/10.3390/molecules23082028
Fana M, Gallien J, Srinageshwar B, Dunbar GL, Rossignol J (2020) PAMAM dendrimer nanomolecules utilized as drug delivery systems for potential treatment of glioblastoma: a systematic review. Int J Nanomedicine 15:2789–2808. https://doi.org/10.2147/IJN.S243155
Janiszewska J, Posadas I, Játiva P, Bugaj-Zarebska M, Urbanczyk-Lipkowska Z, Ceña V (2016) Second generation amphiphilic poly-lysine dendrons inhibit glioblastoma cell proliferation without toxicity for neurons or astrocytes. PLoS One 11(11):e0165704. https://doi.org/10.1371/journal.pone.0165704
Zeng Y, Kurokawa Y, Win-Shwe TT, Zeng Q, Hirano S, Zhang Z, Sone H (2016) Effects of PAMAM dendrimers with various surface functional groups and multiple generations on cytotoxicity and neuronal differentiation using human neural progenitor cells. J Toxicol Sci 41(3):351–370. https://doi.org/10.2131/jts.41.351
Aso E, Martinsson I, Appelhans D, Effenberg C, Benseny-Cases N et al (2019) Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine 17:198–209. https://doi.org/10.1016/j.nano.2019.01.010
Al-Azzawi S, Masheta D, Guildford AL, Phillips G, Santin M (2018) Dendrimeric poly(epsilon-lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer’s disease. Int J Mol Sci 19(10):3224. https://doi.org/10.3390/ijms19103224
Singh B, Lohan S, Sandhu PS, Jain A, Mehta SK (2016) Functionalized carbon nanotubes and their promising applications in therapeutics and diagnostics. Nanobiomater Med Imaging 455–78. https://doi.org/10.1016/B978-0-323-41736-5.00015-7
Lopez-Suarez L, Awabdh SA, Coumoul X, Chauvet C (2022) The SH-SY5Y human neuroblastoma cell line, a relevant in vitro cell model for investigating neurotoxicology in human: focus on organic pollutants. Neurotoxicology 92:131–155. https://doi.org/10.1016/j.neuro.2022.07.008
Zhang N, He L, Wu W (2016) Self-assembling peptide nanofibrous hydrogel as a promising strategy in nerve repair after traumatic injury in the nervous system. Neural Regen Res 11(5):717–718. https://doi.org/10.4103/1673-5374.182687
Chowdhury SM, Surhland C, Sanchez Z, Chaudhary P, Suresh Kumar MA, Lee S (2015) Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme. Nanomedicine 11(1):109–118. https://doi.org/10.1016/j.nano.2014.08.001
CN110559454B (2022) Nano Composite Medicine for Diagnosing and Treating Alzheimer’s Disease. Google Patents. https://patents.google.com/patent/CN110559454B/en?q=alzheimer+disease+nano&oq=alzheimer+disease+nano. Accessed 29 June 2023
CN108685875A (2022) A Kind of Natural Nano Grain-Pharmaceutical Composition of Anti-Alzheimer’s Disease and Its Preparation Method and Application – Google Patents. https://patents.google.com/patent/CN108685875A/en?q=alzheimer+disease+nano&oq=alzheimer+disease+nano. Accessed 29 June 2023
CN110507830A (2022) A Kind of Nano-Probe and Its Preparation for Alzheimer Disease Pathogenic Protein – Google Patents. Available online at: https://patents.google.com/patent/CN110507830A/en?q=alzheimer+disease+nano&oq=alzheimer+disease+nano. Accessed 29 June 2023
Castor TP (2013) Combination therapeutics and methods for the treatment of neurodegenerative and other diseases. US Patent No US10828276B2
Castor TP, Alexander JS, Purdum G, Rios JD, Schrott LM, Tyler TA, Vizcaino MI (2019) Drug delivery system and method for the treatment of neuro-degenerative disease. US patent No US20130156822A1
Maron R, Frenkel D, Weiner HL, Burt D (2007) Novel composition in the form of a medicament for neurological disorders. Indian Patent No. 257811
Allon N, Gavish M, Veenman JA (2014) Liposomes for in vivo delivery. WO Patent No 2014/0776709 A1
Cimini A, D’angelo B, Das S, Seal S (2014) Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer’s disease and associated methods. US Patent No 2014/8877207 B2
Frautschy S, Gregory C (2015) Bioavailable curcuminoid formulations for treating Alzheimer’s disease and other age-related disorders. US Patent No 2015/9192644 B2
Rogers SL, Friedhoff LT (1998) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8(1):67–75. https://doi.org/10.1016/s0924-977x(97)00079-5
Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB (2006) Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 245(1–2):127–136. https://doi.org/10.1016/j.jns.2005.08.021
Robinson M, Lee BY, Leonenko Z (2015) Drugs and drug delivery systems targeting amyloid-b in Alzheimer’s disease. AIMS Mol Sci 2(3):332–358. https://doi.org/10.3934/molsci.2015.3.332
Tancredi V, D’Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A, Eusebi F (1992) Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett 146(2):176–178. https://doi.org/10.1016/0304-3940(92)90071-e
Sathya S, Shanmuganathan B, Saranya S, Vaidevi S, Ruckmani K, Pandima Devi K (2017) Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function. Artif Cellsnanomed Biotechnol 25:1–12. https://doi.org/10.1080/21691401.2017.1391822
Shin J, Lee S, Cha M (2017) Neuroprotective effect of single-wall carbon nanotubes with built-in peroxidase-like activity against beta-amyloid-induced neurotoxicity. Medchemcomm 8(3):625–632. https://doi.org/10.1039/C6MD00716C
Farlow MR, Miller ML, Pejovic V (2008) Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25(5):408–422. https://doi.org/10.1159/000122962
Mutlu NB, Değim Z, Yilmaz Ş, Eşsiz D, Nacar A (2011) New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm 37(7):775–789. https://doi.org/10.3109/03639045.2010.541262
Lilienfeld S (2002) Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev 8:159–176. https://doi.org/10.1111/j.1527-3458.2002.tb00221.x
Fazil M, Shadab BS, Sahni JK, Ali J (2012) Nanotherapeutics for Alzheimer’s disease (AD): past, present and future. J Drug Target 20(2):97–113. https://doi.org/10.3109/1061186X.2011.607499
Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C (2011) Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Control Release 152(2):208–231. https://doi.org/10.1016/j.jconrel.2010.11.033
Pitt J, Thorner M, Brautigan D, Larner J, Klein WL (2013) Protection against the synaptic targeting and toxicity of Alzheimer’s-associated Aβ oligomers by insulin mimetic chiro-inositols. FASEB J 27(1):199–207. https://doi.org/10.1096/fj.12-211896
Ciepluch K, Weber M, Katir N, Caminade AM, El Kadib A, Klajnert B, Majoral JP, Bryszewska M (2013) Effect of viologen-phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities. Int J Biol Macromol 54:119–124. https://doi.org/10.1016/j.ijbiomac.2012.12.002
Gauthier S, Molinuevo JL (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement 9(3):326–331. https://doi.org/10.1016/j.jalz.2011.11.005
Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B (2008) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70(1):75–84. https://doi.org/10.1016/j.ejpb.2008.03.009
Soni K, Kukereja BK, Kapur M, Kohli K (2015) Lipid nanoparticles: future of oral drug delivery and their current trends and regulatory issues. Int J Curr Pharm Rev Res 7:1–18
Camps P, Formosa X, Galdeano C, Muñoz-Torrero D, Ramírez L, Gómez E et al (2009) Pyrano(3,2-c)quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem 52(17):5365–5379. https://doi.org/10.1021/jm900859q
Yang G, Wang Y, Tian J, Liu JP (2013) Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE 8:e74916. https://doi.org/10.1371/journal.pone.0074916
Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB (2013) Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm 446:16–23. https://doi.org/10.1016/j.ijpharm.2013.02.014
Singh NA, Mandal AKA, Khan ZA (2016) Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J 15:60. https://doi.org/10.1186/s12937-016-0179-4
Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A (2016) Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Exp Opin Drug Delivery 5247:1–11. https://doi.org/10.1080/17425247.2016.1178237
Li M, Zhao C, Duan T, Ren J, Qu X (2014) New insights into Alzheimer’s disease amyloid inhibition: nanosized metallo-supramolecular complexes suppress aβ-induced biosynthesis of heme and iron uptake in PC12 Cells. Adv Healthcare Mater 3:832–836. https://doi.org/10.1002/adhm.201300470
Ji DK, Zhang Y, Zang Y, Li J, Chen GR, He XP, Tian H (2016) Targeted intracellular production of reactive oxygen species by a 2D molybdenum disulphide glycosheet. Adv Mater 28:9356–9363. https://doi.org/10.1002/adma.201602748
Wang T, Zhu H, Zhuo J, Zhu Z, Papakonstantinou P, Lubarsky G, Lin J, Li M (2013) Biosensor based on ultrasmall MoS2 nanoparticles for electrochemical detection of H2O2 released by cells at the nanomolar level. Anal Chem 85(21):10289–10295. https://doi.org/10.1021/ac402114c
Zhang XD, Wang J, Yang J, Chen J, Shen X, Deng J et al (2016) Highly catalytic nanodots with renal clearance for radiation protection. ACS Nano 10:4511–4519. https://doi.org/10.1021/acsnano.6b00321
Pardo M, Shustermeiseles T, Levinzaidman S, Rudich A, Rudich Y (2014) Low cytotoxicity of inorganic nanotubes and fullerene-like nanostructures in human bronchial epithelial cells: relation to inflammatory gene induction and antioxidant response. Environ Sci Technol 48:3457. https://doi.org/10.1021/es500065z
Bin Y, Li X, He Y, Chen S, Xiang J (2013) Amyloid-β peptide (1–42) aggregation induced by copper ions under acidic conditions. Acta Biochim Biophys Sin 45:570–577. https://doi.org/10.1093/abbs/gmt044
Han Q, Cai S, Yang L, Wang X, Qi C, Yang R, Wang C (2017) Molybdenum disulfide nanoparticles as multifunctional inhibitors against Alzheimer’s disease. ACS Appl Mater, Interfaces 9(25):21116–21123. https://doi.org/10.1021/acsami.7b03816
Ren C, Li D, Zhou Q, Hu X (2020) Mitochondria-targeted Tpp-MoS2 with dual enzyme activity provides efficient neuroprotection through M1/M2 microglial polarization in an Alzheimer’s disease model. Biomaterials 232:119752. https://doi.org/10.1016/j.biomaterials.2019.119752
Wang X, Han Q, Liu X, Wang C, Yang R (2019) Multifunctional inhibitors of β-amyloid aggregation based on MoS2/Aunr nanocomposites with high near-infrared absorption. Nanoscale 11:9185–9919. https://doi.org/10.1039/C9NR01845J
Ghahghaei A, Shahraki S (2016) Inhibitory effect of β-casein on the amyloid fibril formation of aβ1−40 associated with Alzheimer’s disease. Int J Pept Res Ther 22:23–29. https://doi.org/10.1007/s10989-015-9482-8
Keep RF, Jones HC, Drewes LR (2019) The year in review: progress in brain barriers and brain fluid research in 2018. Fluids Barriers CNS 16(1):4. https://doi.org/10.1186/s12987-019-0124-y
Ovais M, Zia N, Ahmad I, Khalil AT, Raza A, Ayaz M et al (2018) Phyto-therapeutic and nanomedicinal approaches to cure Alzheimer’s disease: present status and future opportunities. Front Aging Neurosci 10:284. https://doi.org/10.3389/fnagi.2018.00284
Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT et al (2017) Nanotechnology based theranostic approaches in Alzheimer’s disease management: current status and future perspective. Curr Alzheimer Res 14(11):1164–1181. https://doi.org/10.2174/1567205014666170508121031
Wiggers HJ, Zaioncz S, Cheleski J, Mainardes RM, Khalil NM (2017) Curcumin, a multitarget phytochemical: challenges and perspectives. Stud Natural Prod Chem 53:243–276. https://doi.org/10.1016/B978-0-444-63930-1.00007-7
Tang M, Taghibiglou C (2017) The mechanisms of action of curcumin in Alzheimer’s disease. J Alzheimer’s disease 58(4):1003–1016. https://doi.org/10.3233/JAD-170188
Maiti P, Dunbar GJ (2018) Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci 19(6):1637. https://doi.org/10.3390/ijms19061637
Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S (2014) Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int 2014:394264. https://doi.org/10.1155/2014/394264
Szymusiak M, Hu X, Plata PAL, Ciupinski P, Wang ZJ, Liu YJ (2016) Bioavailability of curcumin and curcumin glucuronide in the central nervous system of mice after oral delivery of nano-curcumin. Int J Pharm 511(1):415–423. https://doi.org/10.1016/j.ijpharm.2016.07.027
Huo X, Zhang Y, Jin X, Li Y, Zhang L (2019) A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer’s disease. J Photochem Photobiol B 190:98–102. https://doi.org/10.1016/j.jphotobiol.2018.11.008
Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y et al (2012) Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE 7(3):e32616. https://doi.org/10.1371/journal.pone.0032616
Chung IM, Subramanian U, Thirupathi P, Venkidasamy B, Samynathan R, Gangadhar BH et al (2020) Resveratrol nanoparticles: a promising therapeutic advancement over native resveratrol. Processes 8(4):458. https://doi.org/10.3390/pr8040458
Zou P, Helson L, Maitra A, Stern ST, McNeil SE (2013) Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm 10(5):1977–1987. https://doi.org/10.1021/mp4000019
Zekry D, Epperson TK, Krause KH (2003) A role for NOX NADPH oxidases in Alzheimer’s disease and other types of dementia? IUBMB Life 55:307–313. https://doi.org/10.1080/1521654031000153049
Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC (2015) Therapeutic applications of curcumin nanoformulations. AAPS J 17(6):1341–1356. https://doi.org/10.1208/s12248-015-9811-z
Doggui S, Sahni JK, Arseneault M, Dao L, Ramassamy C (2012) Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 30(2):377–392. https://doi.org/10.3233/JAD-2012-112141
Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. J Alzheimers Dis 23(1):61–77. https://doi.org/10.3233/JAD-2010-101374
Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR (2010) ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm 7(3):815–825. https://doi.org/10.1021/mp900306x
Palmal S, Maity AR, Singh BK, Basu S, Jana NR, Jana NR (2014) Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry 20(20):6184–6191. https://doi.org/10.1002/chem.201400079
Kakkar V, Kaur IP (2011) Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol 49(11):2906–2913. https://doi.org/10.1016/j.fct.2011.08.006
Doggui S, Belkacemi A, Paka GD, Perrotte M, Pi R, Ramassamy C (2013) Curcumin protects neuronal-like cells against acrolein by restoring Akt and redox signaling pathways. Mol Nutr Food Res 57(9):1660–1670. https://doi.org/10.1002/mnfr.201300130
Baliga MS, Shivashankara AR, Venkatesh S, Bhat HB, Palatty PL, Bhandari G, Rao S (2019) Phytochemicals in the prevention of ethanol-induced hepatotoxicity: a revisit. Dietary Interventions in Liver Dis. Academic Press 79–89
Cascella M, Bimonte S, Muzio M, Schiavone V, Cuomo A (2017) The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice. Infect Agents Cancer 12(36):1–7. https://doi.org/10.1186/s13027-017-0145-6
Krupkova O, Ferguson SJ, Wuertz-Kozak K (2016) Stability of (−)-epigallocatechin gallate and its activity in liquid formulations and delivery systems. J Nutr Biochem 37:1–12. https://doi.org/10.1016/j.jnutbio.2016.01.002
Salem SA, Hwei NM, Bin Saim A, Ho CC, Sagap I, Singh R (2013) Polylactic-co-glycolic acid mesh coated with fibrin or collagen and biological adhesive substance as a prefabricated, degradable, biocompatible, and functional scaffold for regeneration of the urinary bladder wall. J Biomed Mater Res 101(8):2237–2247. https://doi.org/10.1002/jbm.a.34518
Nance E, Timbie K, Miller GW, Song J, Louttit C, Klibanov AL et al (2014) Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. J Control Release 189:123–132. https://doi.org/10.1016/j.jconrel.2014.06.031
Prabhakar K, Muzammil Afzal S, Surender G, Kishan V (2013) Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B 3(5):345–353. https://doi.org/10.1016/j.apsb.2013.08.001
Ohishi T, Goto S, Monira P, Isemura M (2016) Anti-inflammatory action of green tea. Anti Inflamm Anti-Allergy Agents Med Chem 15(2):74–90. https://doi.org/10.2174/1871523015666160915154443
Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 43(1):1–16. https://doi.org/10.1016/s0165-0173(03)00174-7
Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, Bush AI (1997) Zinc-induced Alzheimer’s Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem 272(42):26464–26470. https://doi.org/10.1074/jbc.272.42.26464
Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA et al (2000) Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer’s disease. J Struct Biol 130(2–3):209–216. https://doi.org/10.1006/jsbi.2000.4285
Eslami M, Nikkhah SJ, Hashemianzadeh SM, Sajadi SA (2016) The compatibility of Tacrine molecule with poly(n-butylcyanoacrylate) and chitosan as efficient carriers for drug delivery: a molecular dynamics study. Eur J Pharm Sci 82:79–85. https://doi.org/10.1016/j.ejps.2015.11.014
Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W et al (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer’s amyloid beta. J Neurochem 69(5):1995–2004. https://doi.org/10.1046/j.1471-4159.1997.69051995.x
Prakapenka AV, Bimonte-Nelson HA, Sirianni RW (2017) Engineering poly(lactic-co-glycolic acid) (PLGA) micro- and nano-carriers for controlled delivery of 17β-estradiol. Ann Biomed Eng 45(7):1697–1709. https://doi.org/10.1007/s10439-017-1859-8
Wang Y, Balaji V, Kaniyappan S, Krüger L, Irsen S, Tepper K (2017) The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener 12(1):5. https://doi.org/10.1186/s13024-016-0143-y
Al-Suhaimi EA, Nawaz M, Khan FA, Aljafary MA, Baykal A, Homeida AM (2021) Emerging trends in the delivery of nanoformulated oxytocin across blood-brain barrier. Int J Pharm 609:121141. https://doi.org/10.1016/j.ijpharm.2021.121141
Zhang Y, Zou Z, Liu S, Miao S, Liu H (2022) Nanogels as novel nanocarrier systems for efficient delivery of CNS therapeutics. Front Bioeng Biotechnol 10:954470. https://doi.org/10.3389/fbioe.2022.954470
Higashida H, Furuhara K, Lopatina O, Gerasimenko M, Hori O, Hattori T et al (2022) Oxytocin dynamics in the body and brain regulated by the receptor for advanced glycation end-products, CD38, CD157, and nicotinamide riboside. Front Neurosci 16:858070. https://doi.org/10.3389/fnins.2022.858070
Glat M, Skaat H, Menkes-Caspi N, Margel S, Stern EA (2013) Age-dependent effects of microglial inhibition in vivo on Alzheimer’s disease neuropathology using bioactive-conjugated iron oxide nanoparticles. J Nanobiotechnology 11:32. https://doi.org/10.1186/1477-3155-11-32
Gadhave K, Bolshette N, Ahire A, Pardeshi R, Thakur K, Trandafir C et al (2016) The ubiquitin proteasomal system: a potential target for the management of Alzheimer’s disease. J Cell Mol Med 20(7):1392–1407. https://doi.org/10.1111/jcmm.12817
Xie B, Zhang H, Li X, Dong X, Sun Y (2017) Iminodiacetic acid-modified human serum albumin: a multifunctional agent against metal-associated amyloid β-protein aggregation and cytotoxicity. ACS Chem Neurosci 8(10):2214–2224. https://doi.org/10.1021/acschemneuro.7b00128
Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, Veerhuis R (2015) Clusterin levels in plasma predict cognitive decline and progression to Alzheimer’s disease. J Alzheimers Dis 46(4):1103–1110. https://doi.org/10.3233/JAD-150036
Matsubara E, Frangione B, Ghiso J (1995) Characterization of apolipoprotein J-Alzheimer’s A beta interaction. J Biol Chem 270(13):7563–7567. https://doi.org/10.1074/jbc.270.13.7563
Freese C, Uboldi C, Gibson MI, Unger RE, Weksler BB, Romero IA, Couraud PO, Kirkpatrick CJ (2012) Uptake and cytotoxicity of citrate-coated gold nanospheres: comparative studies on human endothelial and epithelial cells. Part Fibre Toxicol 9:23. https://doi.org/10.1186/1743-8977-9-23
Javed I, Peng G, Xing Y, Yu T, Zhao M, Kakinen A et al (2019) Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nat Commun 10(1):3780. https://doi.org/10.1038/s41467-019-11762-0
Hou K, Zhao J, Wang H, Li B, Li K, Shi X et al (2020) Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease. Nat Commun 11(1):4790. https://doi.org/10.1038/s41467-020-18525-2
Moore KA, Pate KM, Soto-Ortega DD, Lohse S, van der Munnik N, Lim M et al (2017) Influence of gold nanoparticle surface chemistry and diameter upon Alzheimer’s disease amyloid-beta protein aggregation. J Biol Eng 11:5. https://doi.org/10.1186/s13036-017-0047-6
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158(1):47–52. https://doi.org/10.1016/s0022-510x(98)00092-6
Gupta J, Fatima MT, Islam Z, Khan RH, Uversky VN, Salahuddin P (2019) Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease. Int J Biol Macromol 130:515–526. https://doi.org/10.1016/j.ijbiomac.2019.02
Sastre M, Ritchie CW, Hajji N (2015) Metal ions in Alzheimer’s disease brain. JSM Alzheimers Dis Relat Dement 2:1014. https://doi.org/10.1021/acs.accounts.9b00248
Markesbery WR, Ehmann WD (1999) Oxidative stress in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS (eds) Alzheimer disease. Lippincott Williams & Wilkins, Philadelphia, pp 401–414
Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M et al (2008) Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59:43–55. https://doi.org/10.1016/j.neuron.2008.06.018
Robert A, Liu Y, Nguyen M, Meunier B (2015) Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer’s disease. Acc Chem Res 48(5):1332–1339. https://doi.org/10.1021/acs.accounts.5b00119
Alies B, Sasaki I, Proux O, Sayen S, Guillon E, Faller P, Hureau C (2013) Zn impacts Cu coordination to amyloid-β, the Alzheimer’s peptide, but not the ROS production and the associated cell toxicity. Chem Commun (Camb) 49(12):1214–1216. https://doi.org/10.1039/c2cc38236a
Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G et al (2009) Restored degradation of the Alzheimer’s amyloid-β peptide by targeting amyloid formation. J Neurochem 108:1198–1207. https://doi.org/10.1111/j.1471-4159.2009.05870.x
Linkous DH, Adlard PA, Wanschura PB, Conko KM, Flinn JM (2009) The effects of enhanced zinc on spatial memory and plaque formation in transgenic mice. J Alzheimers Dis 18(3):565–579. https://doi.org/10.3233/JAD-2009-1162
Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G (2017) Advances in Alzheimer’s diagnosis and therapy: the implications of nanotechnology. Trends Biotechnol 35(10):937–953. https://doi.org/10.1016/j.tibtech.2017.06.002
Hyung SJ, DeToma AS, Brender JR, Lee S, Vivekanandan S, Kochi A et al (2013) Insights into antiamyloidogenic properties of the green tea extract (−)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc Natl Acad Sci U S A 110(10):3743–3748. https://doi.org/10.1073/pnas.1220326110
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60(12):1685–1691. https://doi.org/10.1001/archneur.60.12.1685
LeVine H 3rd, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE (2009) Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1–42) oligomer assembly. Neurosci Lett 465(1):99–103. https://doi.org/10.1016/j.neulet.2009.08.002
Zhang Y, Zhou M (2019) A critical review of the application of chelating agents to enable Fenton and Fenton-like reactions at high pH values. J Hazard Mater 362:436–450. https://doi.org/10.1016/j.jhazmat.2018.09.035
Bareggi SR, Cornelli U (2012) Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther 18:41–46. https://doi.org/10.1111/j.1755-5949.2010.00231.x
Hadavi D, Poot AA (2016) Biomaterials for the treatment of Alzheimer’s disease. Front Bioeng Biotechnol 4:49. https://doi.org/10.3389/fbioe.2016.00049
Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10(4):317–325. https://doi.org/10.1080/10611860290031877
Li M, Guan Y, Ding C, Chen Z, Ren J, Qu X (2016) An ultrathin graphitic carbon nitride nanosheet: a novel inhibitor of metal-induced amyloid aggregation associated with Alzheimer’s disease. J Mater Chem B 4(23):4072–4075. https://doi.org/10.1039/c6tb01215a
Liu G, Men P, Kudo W, Perry G, Smith MA (2009) Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 455(3):187–190. https://doi.org/10.1016/j.neulet.2009.03.064
Harris SA, Harris EA (2018) Molecular mechanisms for herpes simplex virus type 1 pathogenesis in Alzheimer’s disease. Front Aging Neurosci 10:48. https://doi.org/10.2147/IJN.S195218
ElAli A, Rivest S (2016) Microglia in Alzheimer’s disease: a multifaceted relationship. Brain Behav Immun 55:138–150. https://doi.org/10.1016/j.bbi.2015.07.021
Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13. https://doi.org/10.12703/P6-13
Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB (2013) Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res 57(9):1510–1528. https://doi.org/10.1002/mnfr.201100741
Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC et al (2012) Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 12(2):368–377. https://doi.org/10.1016/j.intimp.2011.12.009
Songjiang Z, Lixiang W (2009) Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech 10(3):900–905. https://doi.org/10.1208/s12249-009-9279-1
Wang ZY, Liu JG, Li H, Yang HM (2016) Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer’s disease: a review. Am J Chin Med 44(8):1525–1541. https://doi.org/10.1142/S0192415X16500853
Kik K, Bukowska B, Sicinska P (2020) Polystyrene nanoparticles: sources, occurrence in the environment, distribution in tissues, accumulation and toxicity to various organisms. Environ Pollut 262:114297. https://doi.org/10.1016/j.envpol.2020.114297
Liu G, Men P, Perry G, Smith MA (2009) Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer’s disease. J Nanoneurosci 1:42–55. https://doi.org/10.1166/jns.2009.005
Fritea L, Banica F, Costea TO, Moldovan L, Dobjanschi L, Muresan M, Cavalu S (2021) Metal nanoparticles and carbon-based nanomaterials for improved performances of electrochemical (bio)sensors with biomedical applications. Materials (Basel) 14(21):6319. https://doi.org/10.3390/ma14216319
Lohan S, Raza K, Mehta SK, Bhatti GK, Saini S, Singh B (2017) Anti-Alzheimer’s potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int J Pharm 530(1–2):263–278. https://doi.org/10.1016/j.ijpharm.2017.07.080
Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM (2005) Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurotherapeutics 2:554–571. https://doi.org/10.1602/neurorx.2.4.554
Gopalan D, Pandey A, Udupa N, Mutalik S (2020) Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: role of surface engineered nanocarriers. J Control Release 319:183–200. https://doi.org/10.1016/j.jconrel.2019.12.034
Costa PM, Wang JTW, Morfin JF, Khanum T, To W, Sosabowski J et al (2018) Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting Pittsburgh compound B (PiB)-derived ligands. Nanotheranostics 2:168. https://doi.org/10.7150/ntno.23125
Fabbro A, Prato M, Ballerini L (2013) Carbon nanotubes in neuroregeneration and repair. Adv Drug Deliv Rev 65(15):2034–2044. https://doi.org/10.1016/j.addr.2013.07.002
Georgakilas V, Kordatos K, Prato M, Guldi DM, Holzinger M, Hirsch A (2002) Organic functionalization of carbon nanotubes. J Am Chem Soc 124(5):760–761. https://doi.org/10.1021/ja016954m
Bilal M, Barani M, Sabir F, Rahdar A, Kyzas GZ (2020) Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: an overview. NanoImpact 20:100251. https://doi.org/10.1016/j.impact.2020.100251
Sharma A, Das J (2019) Small molecules derived carbon dots: synthesis and applications in sensing, catalysis, imaging, and biomedicine. J Nanobiotechnol 17(1):92. https://doi.org/10.1186/s12951-019-0525-8
Lee BS, Lin SC, Wu WJ, Wang XY, Chang PZ, Lee CK (2009) Piezoelectric MEMS generators fabricated with an aerosol deposition PZT thin film. J Micromech Microeng 19(6):065014. https://doi.org/10.1088/0960-1317/19/6/065014
Guo Q, Shen XT, Li YY, Xu SQ (2017) Carbon nanotubes-based drug delivery to cancer and brain. J Huazhong Univ Sci Technolog Med Sci 37(5):635–641. https://doi.org/10.1007/s11596-017-1783-z
Wang X, Sun K, Tan YP, Wu SS, Zhang JS (2014) Efficacy and safety of selenium nanoparticles administered intraperitoneally for the prevention of growth of cancer cells in the peritoneal cavity. Free Radic Biol Med 72:1–10. https://doi.org/10.1016/j.freeradbiomed.2014.04.003
Rayman MP (2012) Selenium and human health. Lancet 379:1256–1268. https://doi.org/10.1016/S0140-6736(11)61452-9
Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI et al (2009) Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69:1712–1716. https://doi.org/10.1158/0008-5472.CAN-08-3978
Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer’s disease: beyond APP, PSENs and APOE. Neurobiol Aging 33:437–456. https://doi.org/10.1016/j.neurobiolaging.2010.03.025
Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J (2015) Sialic acid (SA)-modified selenium nanoparticles coated with a high blood–brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease. Acta Biomater 25:172–183. https://doi.org/10.1016/j.actbio.2015.06.035
Croissant JG, Fatieiev Y, Almalik A, Khashab NM (2018) Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications. Adv Healthc Mater 7(4):1700831. https://doi.org/10.1002/adhm.201700831
Croissant JG, Fatieiev Y, Khashab NM (2017) Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv Mater 29(9):1604634. https://doi.org/10.1002/adma.201604634
Ye Y, Hui L, Lakpa KL, Xing Y, Wollenzien H, Chen X, Zhao JX, Geiger JD (2019) Effects of silica nanoparticles on endolysosome function in primary cultured neurons1. Can J Physiol Pharmacol 97(4):297–305. https://doi.org/10.1139/cjpp-2018-0401
Javdani N, Rahpeyma SS, Ghasemi Y, Raheb J (2019) Effect of superparamagnetic nanoparticles coated with various electric charges on alpha-synuclein and beta-amyloid proteins fibrillation process. Int J Nanomedicine 14:799–808. https://doi.org/10.2147/IJN.S190354
Tauran Y, Brioude A, Coleman AW, Rhimi M, Kim B (2013) Molecular recognition by gold, silver and copper nanoparticles. World J Biol Chem 4(3):35–63. https://doi.org/10.4331/wjbc.v4.i3.35
Brambilla D, Verpillot R, Le Droumaguet B, Nicolas J, Taverna M, Kóňa J et al (2012) PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano 6(7):5897–5908. https://doi.org/10.1021/nn300489k
Kiyatkin EA, Sharma HS (2009) Permeability of the blood-brain barrier depends on brain temperature. Neurosci 161(3):926–939. https://doi.org/10.1016/j.neuroscience.2009.04.004
Dao P, Ye F, Liu Y, Du ZY, Zhang K, Dong CZ, Meunier B, Chen H (2017) Development of phenothiazine-based theranostic compounds that act both as inhibitors of β-amyloid aggregation and as imaging probes for amyloid plaques in Alzheimer’s disease. ACS Chem Neurosci 8(4):798–806. https://doi.org/10.1021/acschemneuro.6b00380
Manimaran M, Kannabiran K (2017) Actinomycetes-mediated biogenic synthesis of metal and metal oxide nanoparticles: progress and challenges. Lett Appl Microbiol 64(6):401–408. https://doi.org/10.1111/lam.12730
Esch F, Fabris S, Zhou L, Montini T, Africh C, Fornasiero P, Comelli G, Rosei R (2005) Electron localization determines defect formation on ceria substrates. Science 309(5735):752–755. https://doi.org/10.1126/science.1111568
Kwon HJ, Cha MY, Kim D, Kim DK, Soh M, Shin K, Hyeon T, Mook-Jung I (2016) Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease. ACS Nano 10(2):2860–2870. https://doi.org/10.1021/acsnano.5b08045
Mir Najib Ullah SN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH, Rahman M (2023) Nanomedicine in the management of Alzheimer’s disease: state-of-the-art. Biomedicines 11(6):1752. https://doi.org/10.3390/biomedicines11061752
Chopra H, Bibi S, Singh I, Kamal MA, Islam F, Alhumaydhi FA, Cavalu S (2022) Nanomedicines in the management of Alzheimer’s disease: current view and future prospects. Front Aging Neurosci 14:879114. https://doi.org/10.3389/fnagi.2022.879114
Acknowledgements
This paper was supported by the KU Research Professor Program of Konkuk University, Seoul, South Korea.
Author information
Authors and Affiliations
Contributions
Conceptualization, writing—original draft preparation: MAA, MT, BV. Writing, editing: TT, AM, GR, MNA, SAA, OO, ND, MAB, RS, EAA-S. All authors have reviewed and approved the final version of the manuscript prior to submission.
Corresponding author
Ethics declarations
Consent for Publication
All authors have given final approval of this version and agreed to publish this article here.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ansari, M.A., Tripathi, T., Venkidasamy, B. et al. Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers. Mol Neurobiol 61, 3042–3089 (2024). https://doi.org/10.1007/s12035-023-03730-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-023-03730-z